Huntsman Cancer Institute At University Of Utah

Editor’s note: This is a developing news story. Please check back soon for updates.

Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line therapies due to clinicians’ unfamiliarity with treatment guidelines and misinformation about toxicities.

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do not receive them, study results showed.

An AI model classified risk for prostate cancer metastasis more accurately than standard guidelines, suggesting the approach could be used to reduce overtreatment or undertreatment.

The use of chatbot tools may be a valuable part of health management strategies to improve access to cancer genetic services, according to study results.

The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.

Women who want breast reconstruction after mastectomy can undergo a shorter radiation therapy regimen without significantly increasing their risk for complications, according to results of a randomized phase 3 trial.

Men with bone pain at diagnosis of metastatic, hormone-resistant prostate cancer had shorter survival than men without bone pain, according to study results.

Rates of next-generation sequencing have increased for individuals with metastatic prostate cancer or advanced urothelial carcinoma over the past several years, but more than half of these individuals still do not undergo testing.

Extended family members of men with severe subfertility or infertility may have an increased risk for several different cancer types, study results published in Human Reproduction showed.